文献速递乳腺癌放疗

基于分期与分子亚型倾向性评分回顾性评估放疗对乳腺癌生存的贡献

Retrospective evaluation of the contribution of radiotherapy to survival in breast cancer treatment with propensity score based on stage and subgroup.
PubMed 文献 · Radiat Oncol · 2024-06-26

该回顾性研究纳入1999年7月至2020年12月间就诊的乳腺癌患者,按分期、1-3枚淋巴结受累及分子亚型分层,采用1:1倾向性评分匹配比较接受与未接受放疗组。匹配后放疗组无病生存期与总生存期均优于未放疗组;Luminal B亚型接受放疗者无病生存期与总生存期获益更明显。

要点

  • Luminal B亚型放疗组无病生存期264.83±4.95个月 vs 未放疗组187.09±11.06个月(P<.001)。

核心结论

  • 放疗通过降低局部区域复发和全身转移率提高乳腺癌长期生存率,Luminal B浸润性乳腺癌患者较其他亚型从放疗中获益更显著。

研究设计与样本

  • 经机构审查委员会批准,回顾性分析1999年7月至2020年12月间大学医学院放射肿瘤科与肿瘤内科收治的乳腺癌患者记录。
  • 采用最优匹配算法(optimum,1:1)在接受与未接受放疗组间进行倾向性评分匹配。
  • 匹配后采用Kaplan-Meier法计算无病生存期与总生存期,并用单因素和多因素Cox回归分析估计风险比。

主要发现

  • Luminal B亚型放疗组与未放疗组无病生存期分别为264.83±4.95个月(255.13-274.54)与187.09±11.06个月(165.41-208.78),P<.001;总生存期分别为252.29±10.54个月(231.62-272.97)与197.74±9.72个月(178.69-216.80),P=.001。

关键数值与推荐

  • 按分期、1-3枚淋巴结受累及Luminal A、Luminal B、TNBC、HER2-enriched分子亚型进行分层分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer has been a disease in which treatment strategy has changed over time under the influence of different hypotheses and evidence for more than a century. We analyzed the contribution of radiotherapy to disease-free survival and overall survival by classifying according to stage, 1-3 lymph node involvement, and molecular subgroups. METHODS: Following the approval of the Institutional Review Board, records of patients with breast cancer who were admitted to University School of Medicine Departments of Radiation Oncology and Medical Oncology between July 1999 and December 2020 were reviewed. Using data propensity score matching was performed between the groups that did and did not receive radiotherapy using an optimal matching algorithm (optimum, 1:1). Disease-free survival and overall survival after propensity score matching were calculated using the Kaplan-Meier method. Univariate and multivariate Cox regression analysis was used to estimate hazard ratios. RESULTS: In the radiotherapy and non-radiotherapy groups, disease-free survival was 257.42 ± 5.46 (246.72- 268.13), 208,96 ± 8,15 (192,97-224,94) months respectively, (p = < 0.001), overall survival was 272,46 ± 8,68 (255,43-289,49), 219,05 ± 7,32 (204,70-233,41) months respectively (p = .002). We compared the 19 N1 patient groups who received radiotherapy with the 19 patients who did not receive radiotherapy and calculated the disease-free survival times was 202,21 ± 10,50 (181,62-222,79) and 148,82 ± 24,91 (99,99-197,65) months respectively (p = .011) and overall survival times was 200,85 ± 12,79 (175,77-225,92) and 166,90 ± 20,39 (126,93-206,82) months respectively (p = .055). We examined disease-free survival and overall survival times in both groups according to Luminal A, Luminal B, TNBC, and HER2-enriched subgroups. In the Luminal B subgroup, the disease-free survival duration in the groups receiving radiotherapy and not receiving radiotherapy was 264.83 ± 4.95 (255.13-274.54) and 187.09 ± 11.06 (165.41-208.78) months (p < .001), and overall survival times were 252.29 ± 10.54 (231.62-272.97) and 197.74 ± 9.72 (178.69-216.80) months (p = .001) respectively. CONCLUSIONS: Thanks to studies proving that RT increases long-term survival rates in breast cancer as a result of reducing locoregional recurrence and systemic metastasis rates, it has been understood that the spectrum hypothesis is the hypothesis that most accurately describes breast cancer to date. We found that patients with Luminal B invasive breast cancer benefited significantly more from RT compared to other subgroups.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Cosar R, Sut N, Parlar S, et al. Retrospective evaluation of the contribution of radiotherapy to survival in breast cancer treatment with propensity score based on stage and subgroup. Radiat Oncol. 2024. PMID: 38926743. doi:10.1186/s13014-024-02474-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。